INOTUZUMAB OZOGAMICIN
Manner of administration:Injection
Restriction
Indication: Acute lymphoblastic leukaemia
Treatment phase: Consolidation treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 2820 mcg | # of repeats: 4 | DPMA: $38,021.29 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Besponsa
(inotuzumab ozogamicin 1 mg injection, 1 vial)
|
||||
Manner of administration:Injection
Restriction
Indication: Acute lymphoblastic leukaemia
Treatment phase: Induction treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 3384 mcg | # of repeats: 2 | DPMA: $50,649.42 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Besponsa
(inotuzumab ozogamicin 1 mg injection, 1 vial)
|
||||
Manner of administration:Injection
Restriction
Indication: Acute lymphoblastic leukaemia
Treatment phase: Consolidation treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 2820 mcg | # of repeats: 4 | DPMA: $37,452.57 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Besponsa
(inotuzumab ozogamicin 1 mg injection, 1 vial)
|
||||
Manner of administration:Injection
Restriction
Indication: Acute lymphoblastic leukaemia
Treatment phase: Induction treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 3384 mcg | # of repeats: 2 | DPMA: $49,906.35 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Besponsa
(inotuzumab ozogamicin 1 mg injection, 1 vial)
|
||||